Journey Medical Corporation (DERM)Healthcare | Drug Manufacturers - Specialty & Generic | Scottsdale, United States | NasdaqCM
4.98 USD
-0.14
(-2.829%) ⇩
(Oct. 16, 2026, 11:26 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:27 a.m. EDT
Journey Medical presents a classic case of a 'strong buy' analyst recommendation colliding with a fundamentally broken balance sheet. While the company boasts impressive top-line growth—revenue expanded 23% year-over-year—and holds a portfolio of nine FDA-approved dermatology drugs, the bottom line is hemorrhaging cash. Free cash flow and operating cash flow are both deeply negative, and the company is burning through its meager cash reserves while carrying debt nearly equal to its cash on hand. This financial fragility is reflected in the negative forward P/E and negative return on equity, indicating that current operations are destroying shareholder value despite the product pipeline. The price action tells a story of exhaustion rather than breakout potential. Despite a massive 195% gain over the last three years, the stock has been grinding lower recently, trading well below its 50-day and 200-day moving averages. The market appears to be pricing in the risk of dilution or bankruptcy rather than the potential of the drug portfolio. With no dividend to provide income and a statistical forecast model showing low confidence in any immediate price direction, there is no clear catalyst to justify a speculative entry at these levels. The gap between the optimistic analyst targets and the deteriorating financial reality creates a dangerous setup for investors chasing the 'strong buy' label without verifying the solvency of the issuer. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.096100 |
| AutoETS | 0.102071 |
| AutoARIMA | 0.102410 |
| MSTL | 0.110582 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 12.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.151 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 79.532 |
| Revenue per Share | 2.552 |
| Market Cap | 140,557,488 |
| Forward P/E | -83.00 |
| Beta | 1.11 |
| Profit Margins | -8.95% |
| Website | https://journeymedicalcorp.com |
As of Oct. 10, 2026, 7:27 a.m. EDT: Speculator positioning is extremely thin and fragmented. Call volume is negligible across all expirations, with open interest concentrated at the money ($7.50) for near-term contracts and slightly out-of-the-money for February 2027. Put activity is similarly sparse, with minimal open interest at strikes significantly below the current price. The lack of meaningful volume or open interest suggests a lack of active directional conviction from retail or institutional traders, resulting in a flat, low-liquidity environment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28819442 |
| Address1 | 9,237 East Via de Ventura Blvd. |
| Address2 | Suite 105 |
| All Time High | 10.2 |
| All Time Low | 1.02 |
| Ask | 6.55 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 190,810 |
| Average Daily Volume3 Month | 188,448 |
| Average Volume | 188,448 |
| Average Volume10Days | 190,810 |
| Beta | 1.111 |
| Bid | 3.71 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.161 |
| City | Scottsdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.98 |
| Current Ratio | 1.59 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 5.18 |
| Day Low | 4.93 |
| Debt To Equity | 79.532 |
| Display Name | Journey Medical |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,566,600 |
| Earnings Call Timestamp Start | 1,786,566,600 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | 1,216,000 |
| Ebitda Margins | 0.01783 |
| Enterprise To Ebitda | 118.872 |
| Enterprise To Revenue | 2.12 |
| Enterprise Value | 144,548,032 |
| Eps Forward | -0.06 |
| Eps Trailing Twelve Months | -0.22 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.8594 |
| Fifty Day Average Change | -1.8793998 |
| Fifty Day Average Change Percent | -0.27398896 |
| Fifty Two Week Change Percent | -28.819443 |
| Fifty Two Week High | 9.555 |
| Fifty Two Week High Change | -4.5750003 |
| Fifty Two Week High Change Percent | -0.4788069 |
| Fifty Two Week Low | 4.31 |
| Fifty Two Week Low Change | 0.6700001 |
| Fifty Two Week Low Change Percent | 0.15545246 |
| Fifty Two Week Range | 4.31 - 9.555 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,636,727,400,000 |
| Float Shares | 15,592,849 |
| Forward Eps | -0.06 |
| Forward P E | -83.0 |
| Free Cashflow | -5,463,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 58 |
| Fullday Change | -0.14499998 |
| Fullday Change Percent | -2.829268 |
| Fullday Price | 4.98 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.65450996 |
| Gross Profits | 44,625,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31753 |
| Held Percent Institutions | 0.47944 |
| Implied Shares Outstanding | 28,224,395 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,021-11-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. |
| Long Name | Journey Medical Corporation |
| Market | us_market |
| Market Cap | 140,557,488 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_280596341 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,104,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 183,740,811 |
| Number Of Analyst Opinions | 4 |
| Open | 5.17 |
| Operating Cashflow | -7,492,000 |
| Operating Margins | 0.02464 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 480 434 6670 |
| Previous Close | 5.125 |
| Price Hint | 4 |
| Price To Book | 4.289406 |
| Price To Sales Trailing12 Months | 2.0615346 |
| Profit Margins | -0.08953 |
| Quick Ratio | 1.352 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.14499998 |
| Regular Market Change Percent | -2.829268 |
| Regular Market Day High | 5.18 |
| Regular Market Day Low | 4.93 |
| Regular Market Day Range | 4.93 - 5.18 |
| Regular Market Open | 5.17 |
| Regular Market Previous Close | 5.125 |
| Regular Market Price | 4.98 |
| Regular Market Time | 1,792,164,395 |
| Regular Market Volume | 51,466 |
| Return On Assets | -0.02095 |
| Return On Equity | -0.23768999 |
| Revenue Growth | 0.233 |
| Revenue Per Share | 2.552 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 22,224,395 |
| Shares Percent Shares Out | 0.1083 |
| Shares Short | 3,055,846 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,961,399 |
| Short Name | Journey Medical Corporation |
| Short Percent Of Float | 0.1928 |
| Short Ratio | 17.61 |
| Source Interval | 15 |
| State | AZ |
| Symbol | DERM |
| Target High Price | 15.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 13.75 |
| Target Median Price | 13.5 |
| Total Cash | 25,643,000 |
| Total Cash Per Share | 0.909 |
| Total Debt | 25,541,000 |
| Total Revenue | 68,181,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.776425 |
| Two Hundred Day Average Change | -1.7964249 |
| Two Hundred Day Average Change Percent | -0.2650992 |
| Type Disp | Equity |
| Volume | 51,466 |
| Website | https://journeymedicalcorp.com |
| Zip | 85,258 |